Intensity Therapeutics, Inc. ( INTS ) shares are tumbling on Friday following the announcement of a 1-for-25 reverse stock split to increase the per-share trading price and comply with Nasdaq listing requirements.

The stock’s decline comes as broader markets are experiencing gains, with the S&P 500 up 0.24% and the Nasdaq rising 0.29%.

The reverse stock split, approved by shareholders in October 2025, is set to take effect at 4:01 p.m. Eastern Time on February 18, 2026, with trading on a post-split adjusted basis beginning on February 19, 2026. This move will reduce the number of outstanding shares from approximately 63.3 million to about 2.5 million, which is expected to help the company regain compliance with Nasdaq’s minimum bid price requirement.

In addition to the split, Intensity Therapeutics ( INTS ) is focused on its lead product candidate, INT230-6, which is designed for direct intratumoral injection.

The company aims to leverage its proprietary DfuseRx technology to enhance the effectiveness of cancer therapies.

The broader market is experiencing positive momentum, with the Technology sector gaining 1.47% today. Despite this, Intensity Therapeutics’ stock is down, indicating that company-specific factors are influencing its performance.

Technical Analysis

The stock is currently trading 30.8% below its 20-day simple moving average (SMA) and 36.1% below its 50-day SMA, indicating significant weakness in its short-term trend.

Over the past 12 months, shares have decreased by 87.94%, and they are positioned closer to their 52-week lows than highs, suggesting ongoing challenges for the company.

The RSI is at 46.41, which is considered neutral territory, while the MACD is above its signal line, indicating a potential bullish signal. The combination of neutral RSI and bullish MACD suggests mixed momentum for the stock.

Key Resistance: 50 cents

Key Support: 20 cents

Earnings Outlook

Looking further out, the next major catalyst for the stock arrives with the March 12, 2026, earnings report.

EPS Estimate: Loss of 5 cents (Up from Loss of 22 cents YoY)

Revenue Estimate: $0.00 M

INTS Price Action: Intensity Therapeutics ( INTS ) shares were down 26.70% at $0.27 at the time of publication on Friday. The stock is near its 52-week low of $0.18, according to Benzinga Pro data.